Product
SPK-8011
Aliases
AAV-Spark200-BDD-hFVIII, Dirloctocogene samoparvovec
3 clinical trials
1 indication
Indication
Hemophilia AClinical trial
Gene-transfer, Open-label, Dose-escalation Study of SPK-8011 [Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene] in Individuals With Hemophilia AStatus: Completed, Estimated PCD: 2023-12-05
Clinical trial
A Multi-Center Evaluation of the Long-Term Safety and Efficacy of Spark-sponsored Gene Therapies in Males With Hemophilia AStatus: Active (not recruiting), Estimated PCD: 2032-12-01
Clinical trial
A Phase 3, Single-arm, Open-label, Multicenter Study of the Safety and Efficacy of Dirloctocogene Samoparvovec (SPK 8011, Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene) in Adults With Severe or Moderately Severe Hemophilia AStatus: Recruiting, Estimated PCD: 2027-05-01